177Lu-Debio-1124

N/A

Report date: 2025/11/20 16:02:31

Base Information

Drug Name177Lu-Debio-1124
Drug Alias NameLithium-177-Debio-1124Debio-1124cholecystokinin B receptor antagonist (Debiopharm)177Lithium-Debio-1124Minigastrin-Lu177 +[7] 
ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionCholecystokinin B receptor antagonists
TargetsCholecystokinin B receptor
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Solid tumoursSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPaul Scherrer Institut
China Registration ClassN/A

Develop Information

Active CompaniesPaul Scherrer Institut
Inactive CompaniesDebiopharm International Sa
Active IndicationsMedullary thyroid cancer (MTC)Solid tumoursSmall Cell Lung Carcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A